Clinical Trial Update: CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) clinical trial update evaluating a CSF CTC-capture-guided combination of EGFR-TKI and bevacizumab in EGFR-mutant advanced non-small cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• EGFR Tyrosine Kinase Inhibitor (EGFR tyrosine kinase inhibitor)

Snippet

Sponsor: Second Affiliated Hospital of Nanchang University | Conditions: Non Small Cell Lung Cancer, Circulating Tumor Cell | EARLY_Phase 1 | Status: NOT_YET_RECRUITING